The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESH MM 2018 | How do we define a ‘cure’ in myeloma?

Name: How do we define a ‘cure’ in myeloma?
Uploaded: 2018-10-06T00:00:00.000Z
Duration: 1 min 56 s
Description: How to we define a 'cure' in multiple myeloma (MM)? We spoke to Annemiek Broyl, MD, PhD, of Erasmus Medical Center and University, Rotterdam, Netherlands, about this important and interesting topic, as well as the role of measurable residual disease (MRD) in this definition, at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Annemiek Broyl • 6 Oct 2018

ESH MM 2018

Multiple Myeloma

How to we define a ‘cure’ in multiple myeloma (MM)? We spoke to Annemiek Broyl, MD, PhD, of Erasmus Medical Center and University, Rotterdam, Netherlands, about this important and interesting topic, as well as the role of measurable residual disease (MRD) in this definition, at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.